Drugs / Avacc 10
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05604690 | Nov 2022 → Aug 2023 | COVID-19 | Intravacc B.V. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Avacc 10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05604690 ↗ |
| Modality | Vaccine | “Intranasal application of either low dose or high dose of Covid 19 vaccine.” NCT05604690 ↗ |
| Route | Intranasal | “Intranasal application of either low dose or high dose of Covid 19 vaccine.” NCT05604690 ↗ |